Skip To Main Content
Lisa Evans DeWald on Muck Rack

Lisa Evans DeWald

As seen in: Nature, MDPI, Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lisa Evans

Contact Lisa Evans, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus

|
By Demetrius Matassov, Lisa Evans DeWald, Stefan Hamm, Rebecca M. Nowak
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (167) Issue with article?

In Vivo Activity of Amodiaquine against Ebola Virus Infection

|
By Anna N Honko, Julie Dyall, Lisa Evans DeWald, Michael R. Holbrook
| Nature Verified
Abstract During the Ebola virus disease (EVD) epidemic in Western Africa (2013‒2016), antimalarial treatment was administered to EVD patients due to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine.
Open in Who Shared Issue with article?

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus

|
By Yu Cong, Lisa Evans DeWald, Julie Dyall
| PLOS
In the fall of 2014, an international news agency reported that patients suffering from Ebola virus disease (EVD) in Liberia were treated successfully with lamivudine, an antiviral drug used to treat human immunodeficiency virus-1 and hepatitis B virus infections. According to the report, 13 out of 15 patients treated with lamivudine survived and were declared free from Ebola virus disease.
Open in Who Shared Issue with article?
See all 4 articles